Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Onconova Therapeutics, Inc. | a2223977z10-k.htm |
| EX-32.1 - EX-32.1 - Onconova Therapeutics, Inc. | a2223977zex-32_1.htm |
| EX-21.1 - EX-21.1 - Onconova Therapeutics, Inc. | a2223977zex-21_1.htm |
| EX-31.1 - EX-31.1 - Onconova Therapeutics, Inc. | a2223977zex-31_1.htm |
| EX-32.2 - EX-32.2 - Onconova Therapeutics, Inc. | a2223977zex-32_2.htm |
| EX-31.2 - EX-31.2 - Onconova Therapeutics, Inc. | a2223977zex-31_2.htm |
| EX-10.26 - EX-10.26 - Onconova Therapeutics, Inc. | a2223977zex-10_26.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Onconova Therapeutics, Inc. | Financial_Report.xls |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 333-191161, Form S-8 No. 333-194228 and Form S-3 No. 333-199219) of our report dated March 30, 2015, with respect to the financial statements of Onconova Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2014.
| /s/ Ernst & Young LLP | ||
Philadelphia, Pennsylvania March 30, 2015 |
Consent of Independent Registered Public Accounting Firm